Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury (HYBOBI2) was a Phase II, exploratory, randomized, double blind, sham-controlled trial of HBO 2 for community-dwelling adults with ...
The study found the 30mg/kg nipocalimab group had a statistically significant durable haemoglobin response by week 24.
Behçet’s syndrome (BS), a chronic vasculitis, leads to recurrent oral ulcers, severely impacting quality of life. Here we report the results of a randomized, double-blind, placebo-controlled trial ...
Morning Overview on MSN
A light-and-sound headset for Alzheimer’s is finishing a major late-stage trial this month
Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease. The HOPE study, a randomized, double-blind, sham-controlled trial of the ...
Clinical trials are designed not just to test whether a treatment works, but to do so in a way that eliminates bias. Two common trial designs—open-label and double-blind—differ sharply in this ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
6don MSN
In vivo CRISPR therapy successfully reduces hereditary angioedema attacks in first phase III trial
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...
The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...
Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...
Across 76 weeks in obesity/overweight without type 2 diabetes, survodutide achieved up to 16.6% mean weight loss versus 3.2% ...
Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant. A new phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results